Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03314662 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,778
- Enrollment target
NCT03314662 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 1,778 participants.
The verdict
NCT03314662, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,778 participants
- Enrollment target
Study Summary
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Interventions
- BIOLOGICAL MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
- BIOLOGICAL Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
- BIOLOGICAL MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,778 participants |
| Start Date | 2017-10-17 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03314662
The ClinicalTrials.gov registry entry for NCT03314662 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,778 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) is the first listed.
NCT03314662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03314662 about?
NCT03314662 is a clinical study titled "Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults". This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B stra...
What is the current status of trial NCT03314662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,778 participants. The study started on 2017-10-17. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT03314662?
The interventions under investigation include: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) (BIOLOGICAL), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) (BIOLOGICAL), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03314662?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.